Sponsor:
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Code:
NCT07872033
Conditions
Hepatic Impairment
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Aleniglipron
Brief summary:
Conditions
Hepatic Impairment
Study ID
NCT07872033
Start date
Oct 29, 2026
Status verified date
Nov, 2026
Completion date
Dec, 2027
Anticipated
Primary completion date
Aug, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
36 participants
Anticipated
Allocation
Non randomized
Intervention Model
Sequential
Primary purpose
Other
Arms
experimental: Participants will receive aleniglipron administered orally Part 1
experimental: Participants will receive aleniglipron administered orally Part 2
Interventions
Aleniglipron
Primary outcome measure
Central contacts
Locations
Research Site
Recruiting
Orlando, Florida, United States, 32809
Contacts
Research Site
Recruiting
San Antonio, Texas, United States, 78215
Contacts
Sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Last update posted
Nov 17, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.